WALDENSTROM MACROGLOBULINEMIA

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can reduce the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers who are…

This early-phase study tests NKX019, a therapy made from donor immune cells (natural killer cells) that are engineered to find and attack cancer cells. It is for adults with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to other treatments…

This study tests an experimental radioactive drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have come back or not responded to standard treatments. The drug is designed to target and kill…

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study tests a chemotherapy-free combination of three drugs (bortezomib, rituximab, and ibrutinib) as a first treatment for people with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this approach can keep the disease from getting worse for at lea…

This study tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) can improve outcomes for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 63 participants will receive the combination for up to …

This study tests a new drug (sonrotoclax) alone or with another drug (zanubrutinib) in people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if the treatment shrinks tumors and controls the disease. About 114 adults with either newly diagnosed or retu…

This study tests a two-drug combination (ixazomib and rituximab) in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This study tests whether adding acalabrutinib to standard rituximab therapy is safe and effective for people with nerve damage (neuropathy) linked to two blood conditions: IgM MGUS or Waldenstrom macroglobulinemia. The main goal is to see if the combination can lower a blood prot…

This early-stage trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have specific types of …

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find the safest dose and to see if the drug can shri…

This study looks at people and families who may be more likely to develop blood or lymph node cancers, such as leukemia or lymphoma. Researchers want to learn about the genetic and environmental factors that raise cancer risk. Participants fill out health questionnaires and provi…